Wockhardt represents a unique low risk high gain potential investment in the Indian Pharma space. It is quite amazing to notice that Wockhardt (CMP RS 865) which is one of the top 10 pharma companies by profits and having one of the highest Return on equity should be quoting at such abysmal valuations. In comparison to its peers it is quoting at nearly 40-50% discount making it a low risk investment.
Given the fact that its turnover is over Rs 5000 crore and has enviable margins of +30%, its only time that the market starts re-rating this stock. On the basis of our conservative estimates we would expect the stock to rally and cover the valuation gap with its peers implying a nearly 70-100% appreciation from current levels over the next 12-18 months.
Further we would not be surprised if Wockhardt were to sharply surprise to the upside on its performance beating our own estimates. For further reading please refer to our following Q4FY12 result update and our initiating coverage reports.
Disclaimer: The views expressed in this article are entirely my own and do not reflect the views of my employer. This report is neither an offer nor a solicitation to purchase or sell securities. The information and views expressed herein are believed to be reliable, but no responsibility (or liability) is accepted for errors of fact or opinion. Writers and contributors may be trading in or have positions in the securities mentioned in their articles. Neither http://winningtrades1.com or myself accepts any liability arising out of the above information/articles.
||Vinit Bolinjkar Head of Research, Ventura Securities Ltd
| Mobile: 0 9730836363